Literature DB >> 19563726

Medical therapy in acute coronary syndromes: which medicines and at what doses?

Dmitriy Kireyev1, Edward C Yun, Brian J Page, William E Boden.   

Abstract

Acute coronary syndrome (ACS) occurs when plaque rupture in a coronary artery is superimposed with thrombus formation. This accounts for 1.7 million hospital admissions in the United States annually and significant morbidity and mortality. Although there are advantages to an invasive approach to treating patients with ACS, the role of medical therapy is vital as an adjunctive treatment to reperfusion therapies and in stabilizing ruptured plaques and modifying the metabolic milieu that predisposes to plaque formation and rupture. This article reviews the most important drug classes for medical treatment of ACS patients, as well as optimal doses. This is an exciting time to be involved in the field of cardiovascular medicine, as we continue to see profound improvement from medical therapy in the morbidity and mortality associated with ACS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19563726     DOI: 10.1007/s11886-009-0039-3

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  47 in total

1.  The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention.

Authors:  Hitinder S Gurm; Dean E Smith; J Stewart Collins; David Share; Arthur Riba; Andrew J Carter; Thomas LaLonde; Eva Kline-Rogers; Michael O'Donnell; Hameem Changezi; Marcel Zughaib; Robert Safian; Mauro Moscucci
Journal:  J Am Coll Cardiol       Date:  2008-02-05       Impact factor: 24.094

2.  Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.

Authors:  Peter H Stone; Nikolay A Gratsiansky; Alexey Blokhin; I-Zu Huang; Lixin Meng
Journal:  J Am Coll Cardiol       Date:  2006-06-15       Impact factor: 24.094

3.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

4.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction).

Authors:  Elliott M. Antman; Daniel T. Anbe; Paul Wayne Armstrong; Eric R. Bates; Lee A. Green; Mary Hand; Judith S. Hochman; Harlan M. Krumholz; Frederick G. Kushner; Gervasio A. Lamas; Charles J. Mullany; Joseph P. Ornato; David L. Pearle; Michael A. Sloan; Sidney C. Smith; Joseph S. Alpert; Jeffrey L. Anderson; David P. Faxon; Valentin Fuster; Raymond J. Gibbons; Gabriel Gregoratos; Jonathan L. Halperin; Loren F. Hiratzka; Sharon Ann Hunt; Alice K. Jacobs; Joseph P. Ornato
Journal:  J Am Coll Cardiol       Date:  2004-08-04       Impact factor: 24.094

5.  Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.

Authors:  James E Tcheng; David E Kandzari; Cindy L Grines; David A Cox; Mark B Effron; Eulogio Garcia; John J Griffin; Giulio Guagliumi; Thomas Stuckey; Mark Turco; Martin Fahy; Alexandra J Lansky; Roxana Mehran; Gregg W Stone
Journal:  Circulation       Date:  2003-08-25       Impact factor: 29.690

6.  Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.

Authors:  Dmitriy N Feldman; S Chiu Wong; Christopher L Gade; David S Gidseg; Geoffrey Bergman; Robert M Minutello
Journal:  Am Heart J       Date:  2007-08-20       Impact factor: 4.749

7.  Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.

Authors:  Marco Valgimigli; Gianluca Campo; Gianfranco Percoco; Leonardo Bolognese; Corrado Vassanelli; Salvatore Colangelo; Nicoletta de Cesare; Alfredo E Rodriguez; Maurizio Ferrario; Raul Moreno; Tommaso Piva; Imad Sheiban; Giampaolo Pasquetto; Francesco Prati; Marco S Nazzaro; Giovanni Parrinello; Roberto Ferrari
Journal:  JAMA       Date:  2008-03-30       Impact factor: 56.272

8.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

9.  Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy.

Authors:  Jeffrey S Berger; Amanda Stebbins; Christopher B Granger; Eric M Ohman; Paul W Armstrong; Frans Van de Werf; Harvey D White; R John Simes; Robert A Harrington; Robert M Califf; Eric D Peterson
Journal:  Circulation       Date:  2007-12-17       Impact factor: 29.690

10.  The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: a new frontier for statins?

Authors:  David Waters; Gregory G Schwartz; Anders G Olsson
Journal:  Curr Control Trials Cardiovasc Med       Date:  2001
View more
  1 in total

1.  Long-term outcomes of high-risk elderly male patients with multivessel coronary disease: optimal medical therapy versus revascularization.

Authors:  Tao Tao; Hao Wang; Shu-Xia Wang; Yu-Tao Guo; Ping Zhu; Yu-Tang Wang
Journal:  J Geriatr Cardiol       Date:  2016-02       Impact factor: 3.327

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.